| dc.creator |
KARAHAN, Nermin |
|
| dc.creator |
BOZKURT, Kemal Kürşat |
|
| dc.creator |
ÇALOĞLU, Eylem |
|
| dc.creator |
ÇİRİŞ, İbrahim Metin |
|
| dc.creator |
KAPUCUOĞLU, Nilgun |
|
| dc.creator |
BAŞPINAR, Şirin |
|
| dc.date |
2011-06-30T21:00:00Z |
|
| dc.date.accessioned |
2020-10-06T10:49:45Z |
|
| dc.date.available |
2020-10-06T10:49:45Z |
|
| dc.identifier |
9935239a-7063-46fe-af9d-fc7a50d97e64 |
|
| dc.identifier |
10.4103/0377-4929.85086 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/9935239a-7063-46fe-af9d-fc7a50d97e64/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/67171 |
|
| dc.description |
Introduction: Basal cell carcinoma (BCC) is the most frequent malignant skin tumor. BCC rarely metastasizes, but it is often locally aggressive. Cyclooxygenase-2 (COX-2) is critical for tumor formation, angiogenesis and metastasis. Matrix metalloproteinases (MMPs) are the members of the family of zinc (Zn)- and calcium-dependent endopeptidases that degrade the extracellular matrix. Materials and Methods: In our study, we used immunohistochemical methods for the evaluation of COX-2, MMP-2 and MMP-9 expression in tissue samples of 30 primary and 10 recurrent skin BCC cases. Results: Immunohistochemical COX-2 expression was significantly higher in the infiltrating pattern of BCC compared with the nodular (P = 0.005) and superficial (P = 0.041) subtypes in the primary BCC group. There was not a significant difference between nodular and superficial BCCs for COX-2 expression. In addition, COX-2 expression was significantly higher in the recurrent BCC group than in the primary BCC group (P = 0.030). There was no statistically significant difference between the histological subtypes of primary BCCs and between primary and recurrent BCCs for MMP-2 and MMP-9 expressions. Conclusions: Our data confirm previous findings that COX-2 and MMP-9 expressions are increased in BCC. Our results revealed an elevated COX-2 expression in recurrent BCCs. We suggest that COX-2 inhibition might have beneficial effects in BCCs, especially for the tumors with a higher level of COX-2 expression or aggressive phenotype. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Increased expression of COX-2 in recurrent basal cell carcinoma of the skin: A pilot study |
|
| dc.type |
info:eu-repo/semantics/article |
|